Our publication of the EAST-AFNET 4 results in the New England Journal of Medicine “Early Rhythm-Control Therapy in Patients with Atrial Fibrillation“ was read over 90.000 (and cited 48) times across all 5 continents. Two “Letters to the Editor” including the answers of the authors were recently released. Please read.
The Smart in OAC – AFNET 9 study is testing whether unknown atrial fibrillation (AF) can be detected via an app and a monitoring bracelet. It is the objective to detect AF at an early stage using modern technologies. The number of newly detected, previously unknown episodes of atrial fibrillation and the effectivity of the program will be evaluated.
Especially in elderly patients, an infection with Covid-19 often takes a severe course. Therefore, AFNET recommends these patients to get vaccinatied as soon as possible. The protection by the vaccination outweighs possible vaccination risks by far.
Patients with newly diagnosed atrial fibrillation (AF) benefit from early rhythm control therapy, according to results of EAST – AFNET 4, an AFNET/EHRA trial presented in a Hot Line session today at ESC Congress 2020[1,2]. Early rhythm control therapy with antiarrhythmic drugs and/or AF ablation reduced a composite of cardiovascular death, stroke, and hospitalization for worsening heart failure or acute coronary syndrome in 2789 patients with early AF and cardiovascular risk factors compared to usual care over a 5-year follow-up time.
ESC Congress 2020 – The Digital Experience
Saturday, 29th August 2020 | 5:00 – 5:30pm (CEST)
We can’t wait to reveal the results of the EAST-AFNET 4 trial on treatment of recent-onsent Atrial Fibrillation today.
Hot Line 3:
EAST – AFNET 4: Effects of Early Rhythm Control Therapy in Patients with Atrial Fibrillation
